Statement on the FDA and HHS enforcement discretion policy for 503a compounding with certain peptides
October 28, 2026 (Washington, D.C.) — Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement regarding the Food and Drug…
DO
By Daniel Okafor · Regulatory Correspondent
Oct 28 19:36 ETSource: Partnership for Safe Medicines
From the source
Read at safemedicines.orgStatement on the FDA and HHS enforcement discretion policy for 503a compounding with certain peptides
October 28, 2026 (Washington, D.C.) — Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement regarding the Food and Drug Administration (FDA) and Department of Health and Human Services’ (HHS) Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances .
